DelveInsight’s, “Diabetes Pipeline Insights 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including Diabetes clinical trials and nonclinical stage products. It also covers the Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Diabetes Pipeline Report

 

• DelveInsight’s Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.

 

• The leading Diabetes Companies include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others

 

• Promising Diabetes Pipeline Therapies include LY2963016, Drug: Lantus, Drug: OAMs, Drug: insulin glargine + exenatide + preexisting metformin, Drug: insulin glargine + sitagliptin + preexisting metformin, Drug: insulin glargine + preexisting metformin, ORMD-0801, Cotadutide, and others.

 

• Diabetes companies and academics are working to assess challenges and seek opportunities that could influence R&D Multiple myeloma. The Diabetes pipeline therapies under development are focused on novel approaches to treat/improve Diabetes.

 

To explore more information on the latest breakthroughs in the Diabetes Pipeline treatment landscape of the report, click here @ Diabetes Pipeline Outlook

 

Diabetes Overview

Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas.

 

Diabetes Emerging Drugs Profile

 

• Enavogliflozin – Daewoong

Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.

 

• Golimumab – Janssen Biotech

Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.

 

For further information, refer to the detailed Diabetes Unmet Needs, Diabetes Market Drivers, and Diabetes Market Barriers, click here for Diabetes Ongoing Clinical Trial Analysis

 

Diabetes Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the therapies for Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. phase III include, Daewoong.

 

Diabetes Pipeline Segmentation

 

Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Request a sample and discover the recent advances in Diabetes Ongoing Clinical Trial Analysis and Medications, click here @ Diabetes Treatment Landscape

 

Scope of the Diabetes Pipeline Report

 

• Coverage- Global

 

• Diabetes Companies- Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others

 

• Diabetes Pipeline Therapies include LY2963016, Drug: Lantus, Drug: OAMs, Drug: insulin glargine + exenatide + preexisting metformin, Drug: insulin glargine + sitagliptin + preexisting metformin, Drug: insulin glargine + preexisting metformin, ORMD-0801, Cotadutide, and others.

 

• Diabetes Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Diabetes Market Drivers and Diabetes Market Barriers, click here @ Diabetes Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Diabetes: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetes – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Diabetes Collaboration Deals
9. Late Stage Products (Phase III)
10. Enavogliflozin: Daewoong
11. Mid Stage Products (Phase II)
12. Golimumab: Janssen Biotech
13. Early Stage Products (Phase II/I)
14. IMCY-0098: ImCyse
15. Pre-clinical and Discovery Stage Products
16. ENT-001: Enthera
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Diabetes Key Companies
20. Diabetes Key Products
21. Diabetes- Unmet Needs
22. Diabetes- Market Drivers and Barriers
23. Diabetes- Future Perspectives and Conclusion
24. Diabetes Analyst Views
25. Diabetes Key Companies
26. Appendix

Got Queries? Find out the related information on Diabetes Mergers and acquisitions, Diabetes Licensing Activities @ Diabetes Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services